Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II , Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Effects of SC0245 in Combination With Irinotecan in Patients With ES-SCLC

NCT05731518 is registered in ClinicalTrials.gov with Biocity Biopharmaceutics Co., Ltd. as lead sponsor.

NCT NCT05731518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05731518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II , Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Effects of SC0245 in Combination With Irinotecan in Patients With ES-SCLC
Lead sponsor
Biocity Biopharmaceutics Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 23, 2023
Completion date
February 28, 2026
Enrollment
67 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer